Pfizer (PFE) and Moderna patent case against Bayer dismissed
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowPfizer (PFE), BioNTech, and Moderna have lost their attempt to dismiss a patent infringement case brought by Bayer. The court's decision allows Bayer to pursue its claim related to the technology used in mRNA vaccines. This ruling may have implications for the patent landscape in the biopharmaceutical industry, potentially affecting how companies protect their innovations. The outcome could influence future litigation involving vaccine patents, which is valuable for investors in this sector.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Pfizer Inc. (PFE)
Pfizer is one of the world’s largest pharmaceutical companies, developing vaccines and medicines across many therapeutic areas.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier PFE news
- Pfizer (PFE) Growth Strategy Discussed at U.S. All Stars Conference
- Pfizer (PFE) to Share Drug Revenue with HHS Under Pricing Deal
- Pfizer (PFE) Discusses Pipeline and AI Focus at Morgan Stanley
- Pfizer Stock Predictions for 2030: Future Trends Examined
- Pfizer (PFE) Earnings Report Upcoming Amid Dividend Concerns
Understand this kind of story
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Fintech Ramp Seeks OCC Trust Bank Charter to Expand Asset Services
Oct 19
Daily Loan Offers Raise Concerns Over Potential Scams
Oct 19
Nestle, Unilever Face Regulatory Action in India for Health Claims
Oct 18
China Plans Export Controls on Solar Tech to Safeguard Industry
Oct 18